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Summary 
The restricted expression of the human Fc3,Rlb gene to mydoid cells is likely to be regulated 
by a combination of transcription factors that may not be solely expressed in myeloid cells, but 
act together to restrict the expression of the gene to myeloid cells. Low basal expression of the 
human Fc3,Rlb gene is specifically upregulated by interferon 3' (IFN-3'). A  181-bp region of 
5' flanking sequence contains several key regulatory motifs that include the extended gamma 
response region (XGRR) and the PIE region. The XGRR contains the 39-bp 3" response region 
originally defined in the highly homologous Fe~Rla gene. The XGRR is in close proximity 
to the 21-bp PIE motif that is conserved in the promoters of some other myeloid genes. The 
PIE motif contains a consensus site for the macrophage and B cell transcription factor, PU.1, 
and is adjacent to the duster of transcription start sites. An active transcription initiator, Iar, 
consensus spans the start sites and appears to direct transcription initiation of this TATA-less 
gene. In this study, we demonstrate that the PIE region contains a functional PU.1 site that 
binds a human PU.l-like protein and that associated factors present in myeloid extracts also bind 
in this PIE region. Mutational analysis reveals an absolute requirement for an intact PU.1 box 
for both basal and IFN-3" inducible expression of this gene. In addition, mutations in the Inr 
greatly reduce basal and inducible transcription. Insertion of a strong TATA box downstream 
from the Inr or at  -30 bp from the transcription start sites restores basal and inducible activity 
in the presence of a mutated PU.1 site. We also demonstrate that indeed, when the XGRR is 
positioned in the context of a heterologous TATA containing promoter, it is able to respond 
equivalently to either IFN-ol or IFN-3". However, IFN-c~ responsiveness does not occur in the 
context of the physiological Fc3,Rlb TATAlless  basal promoter. Our results suggest that a human 
PU.l-like factor acts as a "bridging factor" between the upstream IFN-3" enhancer and the Inr 
dependent preinitiation complex. These findings indicate that the structure of the basal promoter 
in combination with restricted activators  like PU.1 are important in regulating the expression 
of this gene. 
M 
uch progress has been made in understanding how ceU 
surface receptors transduce signals to the cytoplasm 
and nucleus of cells. Recent work on the Fc3,K1 gene yields 
insights into the mechanism of action of IFN-3,. Low basal 
expression of this myeloid gene is rapidly upregalated in re- 
sponse to IFN-3, treatment (1-3).  The biological action of 
this cytokine is mediated via a specific 90-kD receptor (4). 
Ligation of the receptor with ligand results in the phosphory- 
lation of a 91-kD cytoplasmic protein now termed Stat 91 
and an 84-kD protein (5-8), a product of alternative splicing 
of the 91-kD gene. Both proteins are translocated to the nucleus 
and form part of the IFN-inducible transcription complex 
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ISGF-3 (9-11). The Stat 91 protein recognizes an IFN-3,-ac- 
tivated site (GAS) which in part accounts for IFN-3,-induc- 
ible expression of some genes. It now appears that Stat 91 
may be a common component of the signal transduction 
pathway mediated  by a number of cytokines and growth factors 
that include PDGF, EGF, CSF-1, and IL-10 (12-15).  These 
results raise interesting questions as to the specificity of dis- 
crete cellular responses  induced by these various cytokines 
and growth factors that induce a common nuclear transduc- 
tion  pathway.  The  apparent  explanation is  that  growth 
factors/cytokines induce both shared and distinct factors that 
form multimeric complexes (16). 
Work from others highlighted the importance in a GAS 
site that binds Star 91 (10, 17) in a 39-bp enhancer (3, re- 
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Volume 179  June 1994  1985-1996 sponse region,  GRR 1)  in  the  5'  flanking region  of the 
Fc'yKla gene as necessary and sufficient for IFN-% but not 
IFN-ot responsiveness (1, 18). The GRR contains motifs that 
resemble "g interferon response dement ('yIRE), X, and H 
box consensus that resemble dements found in the 5' flanking 
region of MHC class II genes (1). Analysis of the MHC class 
II promoters failed to segregate minimal sequences that were 
sufficient for IFN-3, and IFN-cr responsiveness (19). Instead 
the X, Y, and H  box, which overlaps a GAS site, appears 
to be required to mediate IFN-tx- and IPN-'y-induced ex- 
pression of the human guanylate binding protein gene (7, 
17, 18). The 3' boundary of the GKK at positions -137 to 
-132 has a motif KGAAAAG that resembles a general IFN 
response dement GAAACG (20). Further inspection of the 
region revealed another KGAAAAG motif at position -174 
to - 169 immediataly upstream of the originally defined GRR. 
Indusion of this 5' KGAAAAG in the 60 bp extended GKK 
(XGKK)  allowed an increase of IFN-'y-mediated reporter 
gene expression above that of the GKK (2). These findings 
suggested that this motif may be important in determining 
IFN-3: responsiveness  of this gene. 
A more complete anal) sis of Fc3'Klb gene expression should 
include an attempt to define the precise c/s dements and trans- 
acting factors that mediate mydoid restriction. The Fc3,Klb 
IFN-'y enhancer does not contain myeloid-restricted elements, 
but a conserved 21-bp consensus sequence was localized be- 
tween positions -84 and -104 (numbering from the ATG) 
and may in part account for the mydoid restricted expres- 
sion of this gene (2). A similar concept has been proposed 
for another myeloid gene (reference 21). This c/s motif was 
designated the PIE region as it contains a PU box (P) (5'- 
GAGGAA-3')  and  an  IFN  responsive  dement  (IE)  (5'- 
KGAAAAG-3') (2). A loose consensus of the PIE motif is 
represented in the 5' flanking region of other mydoid-specific 
genes, but whether the motif directly contributes to lineage 
restriction in these genes is not dear. The motif has been 
identified in elastase (22), gp91-phox (23), c-J~s (24), CDllb 
(25),  mig (26),  and cathepsin G  (27).  The factors binding 
the PIE have not yet been identified. It is known, however, 
that more than one factor binds the DNA in this region of 
the core promoter situated adjacent to the transcription start 
sites, and that these factors may be a combination of myeloid 
specific  and common factors, rather than a single unique factor. 
The PIE region contains a potential binding site for PU.1, 
a transcription factor first identified in mice, and expressed 
in B lymphocytes and macrophages (28). PU.1 is a member 
of the Ets family of transcription factors which includes a 
number of factors important in hematopoiesis, such as Etsl, 
Erg, Fli-1, and Spi-1 (reviewed in Macleod et al. [29]). Sev- 
eral Ets family members are expressed  in a tissue-specific 
manner, and may thus regulate tissue-specific gene expres- 
sion (30). PU-1 may cooperate with other trans-acting pro- 
1 Abbreviations  used in this paper:  AdML, Adenovirus major late; EMSA, 
dectrophoretic mobility shift assay; 3,IRE, 3, interferon response element; 
hGH, human growth hormone; Inr, initiator element; tk, thymidine kinase; 
wt, wild-type; XGRR, extended 7 response region. 
teins to enhance transcription. For example, in the murine 
immunoglobulin  r gene 3' enhancer, PU.1 recruits the binding 
of a second B cell spedfic factor, NF-EM5, to a site immedi- 
ately adjacent  to the PU binding site (31), and the interac- 
tion between these two factors is regulated by phosphoryla- 
tion (32). A complex similar to PU.1/NF-EM5 appears to 
be essential to the activity of the immunoglobulin X2-4 en- 
hancer (33). In the CD11b promoter, PU.1 has been shown 
to function in conjunction with the ubiquitously expressed 
factor Spl in enhancing gene expression (34). In the macro- 
phage inflammatory protein la (MIP-la) promoter, binding 
sites for PU.1 and C/EBP overlap, suggesting that competi- 
tion for binding to this site by different factors may be func- 
tionaly important in the regulation of the gene (35). PU.1 
and/or Spi-B contribute to, but are not sufficient for, cell- 
type-specific transcriptional activation of the MIP-la promoter. 
A novel function for PU.1 may be in regulating basal tran- 
scription by binding within the core promoter. This possi- 
bility is suggested by recent work in which the activation 
domain of PU.1 was shown in solid phase assays to bind the 
general transcription factors TFIID and TFIIB that form part 
of the preinitiation KNA polymerase II transcription com- 
plex (36). In the Fc~Rlb TATA-Iess promoter, the presence 
of the PU box overlapping the initiator consensus sequence 
suggests that in this gene PU.1 may interact with the general 
transcription factors of the core promoter. In addition, PU.1 
may act in the Fc'yRlb promoter as a "bridging factor" be- 
tween the core promoter and the upstream IFN-inducible 
enhancer elements. 
The FcyRlb promoter lacks a classical T/ETA and CCAAT 
box, but contains a motif 5-TTTTCTAATTT-3' which con- 
forms to a loose initiator (Inr) consensus sequence (reviewed 
in 37). The Inr overlaps the transcription start site and ap- 
pears to have a role analogous or complementary to the TATA 
box in directing transcription initiation. The proteins that 
bind to the Inr and their interactions have not been fully du- 
cidated.  Some of the molecules that have been suggested as 
binding the Inr are RNA polymerase II, a transcription- 
associated  factor,  TFII-I,  YY1,  and  E2F  (37-41).  In  the 
Fc'yRlb promoter, the PU.1 binding site overlaps the initi- 
ator element but the interaction between the proteins binding 
these sites is unknown. 
In this study, we show that IFN-3' responsiveness of this 
gene is mediated in part by discrete c/s dements, but in addi- 
tion the TATA-Iess structure of the basal promoter that in- 
dudes the tissue restricted activator PU.l-like protein plays 
an important role in determining both mydoid expression 
and the selective IFN-3,  responsiveness of this gene. 
Matariah and Methods 
Cell Culture.  The following cell lines were obtained from the 
American Type Culture Collection (ATCC; R_ockville,  MD) and 
cultured at 37~  in humidified  air with 5% COs, in either ILPMI 
1640 medium or in DME supplemented with 10% FCS (Hyclone 
Laboratories, Inc., Logan, UT), 50 U of penicillln/ml and 50/zg 
of streptomycin/ml: U937, HL60, THPl, PLB (human promy- 
domonocyfic  cell  lines),  HeLa (human  epithelial  carcinoma  cell  line), 
1986  PU.1 Factor and Initiator  Element Fc3,Rlb Gene Expression Daudi and Raji (human B cell lines), Jurkat (human T  cell leu- 
kemic line), mouse erythroid leukemic (MEL) cell line. The mouse 
mast cell line (MC8), a gift from Dr. Mike Gurish (Harvard Med- 
ical School) was cultured in RPMI under similar conditions as those 
described above. 
Preparation of Nuclear Extracts.  Nuclear extracts were prepared 
by the procedure ofDignam et al. (42) or by the procedure of  Licht- 
steiner et al. (43). Since both methods of  extraction produced similar 
results, we present data based on the Dignam method only. In vitro 
transcribed and translated PU.1 cDNA (a gift from Dr. K. Maki, 
La Jolla Cancer Research Foundation, La Jolla, CA) was prepared 
using the TNT Coupled Reticulocyte Lysate System supplied by 
Promega Corp. (Madison, WI). 
Electrophoretic Mobility Shift Assays.  Electrophoretic mobility 
shift assays were performed as previously described with  some 
modifications (31). Oligonucleotides  purified by electrophoresis were 
annealed  (50/2g of each), endlabded with 3,-[s2P]dATP, and the 
unincorporated label separated by passage through a DNA grade 
Sephadex G-50 column (Pharmacia LKB Biotechnology, Piscataway, 
NJ). 5/2g of nuclear extract was incubated on ice for 30 min with 
10,000 cpm ("~0.251 g) of probe in a 30-/21 reaction mixture con- 
taining 12 mM Hepes (pH 7.9), 0.5 mM EDTA, 5 mM MgCI2, 
10% (vol/vol) glycerol, 1 mM dithiothreitol (DTT), 60 mM KC1, 
0.05% NP40, and 21/2g of poly (dI-dC) (Pharmacia LKB Biotech- 
nology). Mixtures were preincubated on ice for 5-10 rain before 
addition of the probe. In competition experiments, unlabeled an- 
nealed oligonucleotides (100-200-fold excess) were added together 
with the nonspedfic competitor poly (dI-dC) for 15 rain before 
the addition of the probe, followed by a further 15-min incubation 
on ice. After incubation, the samples were fractionated at 40C on 
5% polyacryhmide gels (acryhmide/bisacrylamide, 40:1) in 11 mM 
Tris-borate (pH 8.0) and 1 mM EDTA, for 1 h  at 35 mA. 
Antibody supershift assays were performed by preincubating nu- 
clear extracts or in vitro translated PU.1 protein for 15 rain on ice 
with anti-PU.1 antibody or preimmune serum before addition of 
the probe for an additional 15 rain, followed by dectrophoresis. 
The anti-PU.1 antiserum (1297), raised against  the NH2-terminal 
domain of the protein, was  obtained from Dr. R. Maki. 
Transient Transfeaion Assays.  Plasmid constructs were prepared 
by annealing complementary, phosphorylated, synthetic oligonu- 
cleotides containing either the wild-type (wt) XGP,  R. sequence or 
its 5' or 3' deletion. The annealed double stranded fragments were 
constructed to give overhangs compatible with multiple cloning 
sites present in the HSV-thymidine kinase (tk) promoter containing 
CAT reporter gene vector, pBRAMS cat 2 (44) into which these 
were cloned. The point mutation in the construct XGILRA165- 
152 was constructed by annealing synthetic oligonucleotides of the 
sequence:  5 ' -  GATC  CAGGTATGAGCATGGGAAAAGCATCC  - 
ATGGTCCATGC.-GAGATGTATYIC  CCAGAAAAGGAACATG- 3 '; 
5'-GATCCATGTTCCTT TTCTGGGAAATACATCTCCCAT- 
GGACCATGGATGCTTTTCCCATGCTCATACCTG-Y.  Hela 
ceils (10-crn dishes)  were grown to 70% confluence (~107 cells) 
in complete medium (DME with 10% FCS) and transiently trans- 
fected by the DEAE-dextran method. Each dish received 2 ml of 
transfection mixture (DME  +  10% NuSerum [Hyclone Labora- 
tories Inc., Logan, UT] with 250/2g/ml of DEAE-Dextran +  30 
/~g of relevant test plasmid +  5/2g of the constitutively expressing 
human growth hormone plasmid, CMV-GH [Nichols Institute, 
San Juan Capistrano, CA] as the internal control for transfection 
efficiency). After a brief "glycerol shock" step, the ceils were in- 
cubated in complete medium for 24 h. The individual aliquots of 
each originally transfected dish was then subjected to either no fur- 
ther treatment or a 4-h stimuhtion with 300 U/ml of IFN-3~ (Ac- 
timmune; Genentech Inc., South San Francisco, CA) or 600 U/ml 
of IFN-ot (Roferon 2a; Hoffmann-La Roche, Nutley, NJ). The cells 
were then harvested and a cytoplasmic extract was prepared. The 
hGH activity (t/g/ml) in the culture supernate was assayed using 
the Allegro hGH assay kit supplied by Nichols Institute according 
to manufacturer's instructions. The CAT enzyme activity was as- 
sayed according to the protocol suggested by Promega Corp. with 
the exception that the volume of cell extracts used was adjusted 
to equivalent hGH units so as to normalize for minor variations 
in transfection efficiency between dishes.  The reactions were ex- 
tracted in ethyl acetate, spotted onto silica gel-coated TIC plates, 
and developed in chloroform/methanol (98:2 vol/vol). The plates 
were then exposed and analyzed on a phosphor imager with den- 
sitometric quantitation of  the acetyhted chlorarnphenicol spots using 
image analysis software. 
In other experiments, promoter region constructs (- 189 to - 7) 
were transiently transfected into ceils by electroporation. 107 cells 
were washed  twice  with  PBS  and  once in  IMDM,  and  then 
resuspended at a concentration of 107 cells/0.5  ml IMDM for dec- 
troporation (Gene Pulser; Bio-Rad Laboratories,  Richmond, CA). 
The conditions for electroportion of the different cell lines were 
as follows: U937 (300 V, 9,601 F), HeLa (150 V, 9601 F), and Raji 
ceils (200 V, 9601 F). As a control for the efficiency of transfection, 
2/2g of a plasmid containing a human GH gene sequence linked 
to the CMV promoter was cotransfected into the cells. The lu- 
ciferase activity of the experimental phsmids was normalized to 
1/2g of hGH/ml of medium as measured by radioimmunoassay 
(Nichols Institute). Immediately after dectroporation, the cells were 
incubated on ice for 15 min and then returned to the culture medium 
for 8 h before being harvested. IFN-stimuhted cells received 300 U 
of human IFN-3, (Actimmune; a kind gift from Dr. S. Kramer, 
Genentech, Inc.) after the first 4 h of incubation. Luciferase assays 
were performed as described.  Luciferase activity was expressed as 
millivolts per microgram of growth hormone produced per ml in 
the transfection medium (mV//2g GH/ml). 
Luciferase Assay.  Luciferase activity was measured in cells har- 
vested 8 h after transfection. Ceils were pelleted by centrifugation 
at 500 g for 5 min and 100/21 of the superuatant was retained for 
measurement of the cotransfected hGH reporter gene activity. The 
pellet was washed twice in PBS and resuspended in 500/21 of lysis 
buffer (25 mM glycylglycine,  15 mM MgSO4, 4 mM EGTA, 1 
mM DTT, 1% Triton X-100; pH 7.8). Samples were vortexed for 
2 min, centrifuged at 1,200 g at 4~  for 5 min, and the superna- 
tant snap frozen at -80~  For luminometry, samples were thawed 
to room temperature and 300/21 of sample buffer (25 mM glycyl- 
glycine, 15 mM MgSO4, 4 mM EGTA, 1 mM DT~ pH 7.8) was 
added to 100/21 of cell sample, followed by addition of fresh 1 mM 
ATP and 100/21 of ludferin. Luciferase activity was read in mil- 
livolts on a BioOrbit Luminometer 1251 (LKB, Wallac, Finland). 
Plasmid Constructs.  The luciferase reporter gene vectors pGLO1 
and pGLO2 were derived, respectively, from the vectors pBRAMs- 
cat1 and pBRAMS-cat2 (containing the HSV-tk promoter) (44), 
by replacing the CAT gene of the latter vectors with the luciferase 
gene sequences obtained from the vector pGEM-LUC (Promega 
Corp.). 
The 3-bp linker scan mutations of the PIE region were prepared 
by annealing sets of  oligonucleotides containing three base pair trans- 
version mutations at serial positions over the region - 104 to - 79. 
BamHI and NotI cloning sites were included at the ends of the 
annealed  oligonuclentides for subdoning of the fragments into 
pGLO2. 
The 10-bp mutation linker scan constructs were made by oligo- 
nucleotide directed PCP, mutagenesis by substituting a 10-bp linker 
1987  Eichbaum  et al. containing a BgllI site (sequence 5'-AGATCTCAGA-3')  for the wt 
sequence between bp -114 and -44 of the FcTR1 promoter (45). 
The PCR fragments were cloned into the hciferase vector pGLO1 
and each construct was sequenced to confirm correct positioning 
of the oligonucleotide linker. 
The transfection  control phsmid CMV-LUC construct was made 
by replacing the growth hormone gene sequence of the phsmid 
CMV-GH,  with the luciferase gene obtained from the vector 
pGEMluc (Promega Corp.). 
The phsmid CMV-GH was a construct of a human growth hor- 
mone sequence  cloned into the phsmid pUC12 driven by the CMV 
promoter (a gift from Dr. Len Zon, Harvard Medical School). 
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Results 
Mutational IO-BP  Linker Scan of the Basal Promoter Identifies 
Critical Sequences in the PIE and INR Region.  To more pre- 
cisdy define functional motifs that are required for FcTRlb 
basal promoter activity, we carried out a mutational scan using 
a 10-bp linker (-5'-AGATCTCAGA-3') over the region - 104 
to  -44 that was encompassed by the DNase I footprints of 
the region (shown schematically in Fig. 1). Seven linker con- 
structs  (Fig.  2)  inserted  downstream of the  60-bp  IFN- 
y-responsive region (XGRK) in the context of a luciferase 
reporter gene were transfected into U937 cells and assayed 
for luciferase activity with and without IFN-7 treatment. 
A series of three consecutive mutations between  -104 and 
-  74 resulted in a large decrease in luciferase activity that was 
not increased when cells were treated with IFN-7. Almost 
complete loss  of activity  was  observed in  the  construct 
-94/-84  that incorporated the consensus PU.1 binding site 
on the lower strand (5'-GAGGAA-Y). The mutation -104/ 
-94 that incorporated the upstream region of the PIE and 
4 bp at the 5' of the PU motif resulted in a reduction of 
activity to about 25% ofwt activity. A mutation that spanned 
Extended Gamma Response Region (XGRR) 
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Figure  1.  Schematic representation of the FcTR1 promoter indicating 
the location of the (XGRK), the PIE region, Inr, Q region and the tran- 
scription start sites (arrows). The three regions protected (1, 2, and 3) in 
DNase 1 footprinting assays (data not shown) are indicated by bars above 
the sequence. The solid bar indicates strongly footprinted regions and the 
hatched bars represent  regions of weaker protection. 
Figure 2.  Identification of critical c/s dements contained in the FcTRlb 
promoter. (A) Transient transfections  of 10-bp llnk~ scan mutation con- 
structs in the hciferase reporter gene vector pGLO1 and U937 cells that 
were either stimulated for 4 h with human recombinant IFN-7 or un- 
treated. In the diagram, the straight lines represent the wt sequences whereas 
the mutated linker sequence is represented  by the filled in square. The 
position of the mutant linker in the promoter is indicated on the left of 
the diagram. Three independent experiments were performed and the av- 
erage luciferase activities and standard errors were calculated.  Luciferase 
activity, reported in mV, was normalized to 1/~g of growth hormone pro- 
duced per ml of medium by a cotransfected CMV-GH phsmid (Materials 
and Methods). Control plasmids used in each transfection assay are de- 
scribed in Materials and Methods. 
the transcription initiator  -84/-74,  resulted in 10% of lu- 
dferase activity after IFN-7 treatment of transfected cells. 
In addition, a region -54/-44 downstream of the transcrip- 
tion start sites also appeared to contribute to the expression 
of the reporter gene. Our next goal was to define whether 
these functionally important  regions were sites  for DNA 
binding proteins, in particular, a PU.l-like protein and pos- 
sible assodated factors. To investigate this possibility,  we per- 
formed electrophoretic mobility shift assays (EMSA). 
EMSAs Show That PU.I Binds in the PIE Region.  A ra- 
diolabded oligonucleotide probe that represented the PIE re- 
gion containing the PU box was incubated with nuclear ex- 
tracts isolated from 10 different cell lines of hematopoietic 
and epithdial origin and retarded complexes were compared 
in a standard gel shift assay. Extracts from myetoid cell lines 
U937,  THP1,  HL60,  and PLB consistently contained the 
binding activities designated B1 and B2 as shown in Fig. 3. 
Complexes B1 and B2 were both consistently present in only 
the mydoid nuclear extracts, whereas only B1 was present 
in MEL and Raji extracts and B2 was present in Mast (MC8) 
and Daudi extracts. HeLa and Jurkat extracts did not retard 
any specific complexes. A slower mobility complex, running 
above B1, was seen in atl complexes and appeared to be non- 
specific as it could not be competed out with any of the cold 
competitor oligonucleotides (not shown). The B3 complex 
was present only in myeloid extracts, but was relatively un- 
stable and most likely represents a proteolytic fragment of B1. 
Several lines of evidence indicate that a factor with iden- 
tical or similar binding properties to that of PU.1 may ac- 
count for complex B1. The presence of the complex in only 
myetoid and B cell extracts is consistent with the known 
pattern of expression of PU.1. In addition, we show that in 
vitro translated PU.1 protein forms a complex in gel shift 
1988  PU.1  Factor and Initiator Element FcTRlb Gone Expression Figure 3.  E/ViSA  showing  formation  of DNA-protein complexes  be- 
tween the PIE region, oligonucleotide  probe, and nuclear  ~tracts of  var- 
ious myeloid  and non myeloid  cell lines. The probe was prepared as de- 
scribed in Materials and Methods  and the binding reactions with 5/tg 
of nuclear extract were carried out on ice for 30 win in the presence of 
2/tg of poly (dI-dC). The complexes were separated  by dectrophoresis 
through a 5% polyacrylamide  gel (35 mA for 2 h) at 4~  in lx  Ttis- 
buffered  EDTA buffer.  Arrows on the tight indicate  the positions of the 
three comple~es B1, B2, and B3. 
assays with the PIE oligonucleotide that comigrates with com- 
plex B1 present in U937 nuclear extracts (Fig.  4,  lane 1). 
Preincubation of U937 nuclear extract or in vitro translated 
PU.1 protein with anti-PU.1 antiserum that recognizes the 
NHz terminus of the protein resulted in a supershifted mo- 
bility of the B1 complex and in vitro translated PU.1 to similar 
positions in the gel (Fig.  4, lanes 3  and 5).  Preincubation 
with preimmune serum had no effect on the mobility of the 
complexes (Fig. 4; lanes 2 and 4). These results suggest that 
a human protein that is closely related to the murine PU.1 
binds to the PU box within the PIE region of the FcvRlb 
core promoter. 
3-BP Linker Scan of  PIE Region Indicates That PU.I Is Neces- 
sary  for Basal Promoter  Activity.  As the methylation interfer- 
ence patterns of the two complexes were equivocal (results 
not shown), we performed a linker scan of consecutive 3-bp 
Figure 4.  Anti-PU.1  antibody  su- 
pmhift analysis  of U937 nuclear  ex- 
tracts and in vitro  transhted  PU.1. In 
vitro translated  PU.1 or nuclear  ex- 
tracts  of  U937 cells  were  preincu~ted 
on ice for 15 rain with either  preim- 
mune serum or anti-PU.1 serum  be- 
fore  a timber 15-min  incu~tion  with 
the PIE oligonucleotide  probe and 
EMSA under standard conditions. 
(lane 1)  In vitro tramlated PU.1 
without antibody;  (lane  2) U937 ex- 
tracts with preimmune  mama; (lane 
3) U937 extracts  with anti-PU.1 an- 
tibody; (Lane 4) in vitro translated 
PU.1 with preimmune  serum; (lane 
5) in vitro  transhted  PU.1 with anti- 
PU.1 serum. 
mutations across the PIE region and the transcription start 
sites between basepairs  - 104 and -  79 in order to gain some 
understanding of the critical base pairs contacted within this 
region. The unmutated wt and eight additional mutated an- 
nealed oligonucleotides containing NotI and BamHI sites at 
alternate ends for cloning into the luciferase reporter gene 
vectors  (pGLO1 and 2) were assayed in parallel  for both in 
vitro binding and transcriptional activity (Fig. 5, A and C). 
The plasmid pGLO2 containing the tk promoter was used 
since constructs in the promoterless vector pGLO1 showed 
little activity (results  not shown). The low activity may in 
part be due to the exclusion in these constructs of the region 
Q  immediately downstream of the transcription start sites. 
The results of  gel shift assays of the 3-bp PIE mutants (Fig. 
5 A) and the transfections of these constructs into U937 cells 
(Fig. 5 C) indicated a correlation between mutations within 
PU box (M4, M5, M6) that resulted in a loss  of binding 
of  complexes B1 and B2 and of the unstable complex B3 with 
a decrease of between 70 and 50% in reporter gene expres- 
sion. Mutation M3 resulted in an altered pattern of binding 
(Fig.  5 A, lane 3) that correlated with a 50%  reduction in 
reporter gene activity in transfections (Fig.  5 C). The M2 
mutation that defines the 5' boundary of the PIE region also 
encompassed a potential binding site for the myb transcrip- 
1989  Eichbaum  et al. Figure  5.  3 bp mutational scan of the PIE region to identify DNA 
binding motifs. Sets of complementary oligonucleotides incorporating 3-bp 
transversion mutations were annealed and used as probes in gel retardation 
and transient transfection assays to determine factor binding motifs in the 
PIE region. (A) Gel retardation assay showing binding of nuclear extracts 
of U937 cells to wt and mutated oligonuclentide probes (M2-M9) of the 
PIE region. The probes used in each reaction are indicated above the lanes, 
and the complex,  es B1, B2, and B3 are shown on the right. (B) Schematic 
representation of the oligonuclentides representing the 3-bp mutational 
scan across the PIE region. The mutated base pairs are indicated in boxes. 
Lower case letters depict the BamHl and NotI restriction sites used in 
cloning the mutated sequences into pGLO2 for transfection into U937 
and HeLa cells. (C) Transcriptional activity of the 3-bp mutants in U937. 
The mutated oligonucleotide probes of the PIE region were cloned into 
the luciferase reporter gene vector pGLO2 containing the beterologous 
thymidine kinase promoter. The results represent the mean of three inde- 
pendent experiments. 
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tion factor C/EBP (G/CCAAT) and consistently showed a 
decreased intensity in binding of complex B2 (Fig. 5 A, lane 
2), but was not accompanied by a decrease in basal reporter 
gene expression. Mutation M7 that altered the contiguous 
three adenines of the classical PU consensus sequence 5'-AAA- 
GAGGAA-5' (Fig.  5 B) resulted in a marked reduction in 
binding intensity of complexes B1, B2, and B3 in gel shift 
assays (Fig.  5 A, lane 7) and a 50%  reduction in reporter 
gene activity in transfections (Fig. 5 C). Mutant M8 disrupted 
the 3' end of the PIE retained gel shift binding activity, but 
displayed a 55% decrease in reporter gene expression  (Fig. 
5 C). These results provided further evidence for the impor- 
tance of an intact PU.1 site in the basal expression of the gene, 
but also suggested that this region is a composite binding site. 
The PU.1 Site and the Initiator (Inr) Are Required  for Basal 
and IFN-T-Inducible Activity.  Low basal expression of the 
FcTRlb gene is rapidly and specifically upregulated by IFN-7 
treatment. RNA polymerase II directed transcription of this 
gene occurs in the absence  of a TATA box.  Although the 
promoter lacks  a TATA box, it contains a motif spanning 
the transcription start sites that is compatible with that of 
an initiator element (Inr) (5'-TTTTTCTAATTT-3') located 
at the transcription start sites (37).  The 10-bp linker muta- 
tion scan indicated that region  -104 to  -74 contained the 
PU.1 box and the Inr consensus resulted in a reduction in 
IFN-7-inducible reporter gene expression. To more precisely 
define the relative roles of these motifs, we introduced point 
mutations in the PU.1 box (189/7/~PU)  and the Irtr (189/7 
~Inr), respectively (Fig.  1). Mutation of either site resulted 
in a marked reduction in both basal and IFN-7 inducible ex- 
pression and there appeared  to be an absolute requirement 
for an intact PU.1 site. Interestingly, mutations in the GCAAT 
sequence  at the 5' end of the PIE and immediately down- 
stream from the Inr (189/78Q) resulted in a marked reduc- 
tion in transcriptional activity (Fig.  6, A  and B, construct 
189/7ACAAT). These results suggested that both the PIE 
region, which includes the PU site and the Inr and Q  sites, 
are integral components of the basal promoter. 
Responsiveness to IFN-7 and IFN-ce Occurs in the Context 
ofa Heterologous TATA Box.  The XGRR was subcloned into 
a plasmid that contained the chloramphenicol acetyl trans- 
ferase reporter gene CAT and the HSV-tk basal promoter 
(44).  Transient transfection of this plasmid into the human 
epithelial HeLa cell line followed by a 4-h treatment of the 
ceils with IFN-7 resulted in a 25-fold induction of CAT ac- 
tivity (Fig. 7), as previously described (2). However, IFN-o~ 
treatment of the cells transfected with this construct also 
resulted in a 25-fold induction of CAT activity. To determine 
whether distinct or overlapping c/s dements accounted for 
the IFN-ot- and IFN-7-mediated inducible expression, a se- 
ries of 5' and 3' deletion constructs were assembled in the 
tk-CAT vector, pBRAMScat2 (Fig. 7). The construct, 189/147 
tk-CAT, lacks  the 3' RGAAAAG motif, but indudes the 
upstream RGAAAAG dement and the central "),IRE, X, H 
box/GAS site (Fig. 7). This plasmid retained the IFN-c~ in- 
ducible CAT activity, but was unresponsive to induction with 
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Figure 6.  Mutations  of the PIE region (including  the PU box), Inr 
consensus  sequence  and the Q site  reduce  basal  promoter  activity  and IFN-7 
inducibility.  (.4) Schematic  representations  of  mutations  made  in the pro- 
moter. (B) Constructs  depicted  above  were transfected  into U937 cells  and 
assayed for luciferase  activity, both with and without induction of the 
cell by IFN-7. In addition, the effect  of creating a canonical  adenovirus 
major late promoter TATA box sequence by a 3-bp mutation  change up- 
stream of an unmutated  PU box (189/114 TATA 110/7) was tested for 
the ability  to restore transcriptional  activity  and IFN inducibility.  189/7 
is wt sequence from -189 to -7; XGRR-tk is the extended  IFN-7 re- 
sponse element  cloned  into pGLO2  under  control  of the thymidine  kinase 
promoter; 189/7dGag3 is a construct containing  mutations  in the third 
-GAAAG- motif of the promoter that lies immediately  5' of the PIE re- 
gion; 189/7dCAAT  is a mutation  in the CAAT motif situated at the 5' 
end of the PIE region; 189/7dPu is a construct in which all 6 bp of the 
PU box are mutated; 189/7dlnr is the mutated  sequence; 189/7dQ is the 
mutated Q motif; 189 TATA dPU is a sequence containing  an inserted 
AdML  promoter  TATA  box and a mutated  PU box. The results are repre- 
sentative of three independent experiments. 
IFN-7  (Fig.  7,  lane  189/147).  Further deletion of the H 
box/GAS sequence with retention of an intact 7IRE and the 
5'  RGAAAAG motif in  the  construct  189/158  tk-CAT 
1991  Eichbaum  et al. Figure 7.  CAT assay of transiently transfected HeLa 
cells with  various  deletion/mutant constructs  of the 
XGRR in the context of the TATA-containing  heterolo- 
gous  HSV-tk  promoter-CAT  reporter  gene  plasmid, 
pBRAMScat2. NS, No Stimulation; + % 4 h. IFN-'T  stim- 
ulation  (300 U/nil); + or, 4 hours. IFN-ot stimulation (600 
U/ml). The densitometric values in absolute numbers are 
indicated in each lane. 
resulted  in  a  loss of IFN-oL responsiveness (Fig. 7,  lane 
189/158). Transfection of Hela cells with a construct lacking 
the  upstream  5'  RGAAAAG motif,  but  containing  the 
'yIRE/H box/GAS site, and the downstream RGAAAAG 
site, (GRR) resulted in modest IFN-o~ responsiveness  but also 
retained the ability, albeit reduced, to respond to IFN-y when 
compared to wild type XGRR (Fig. 2, lane 169/125). By 
contrast, the IFN-3~ effect appears to be dependent upon the 
two RGAAAAG motifs as translation of a reporter plasmid 
that contains a disrupted ~,IRE, X, H Box/GAS site flanked 
by these two elements is able to induce 40-fold induction 
of CAT activity after IFN-~ treatment (Fig. 7; lane XGRR 
A165-152). 
The observation that the XGRR was unable to mediate 
an IFN-c~-inducible effect when placed upstream of the en- 
dogenous gene promoter, and yet displayed dual cytokine re- 
sponsiveness when in the context of the heterologous TATA 
containing HSV-tk promoter suggested that the structure 
of the basal promoter may play an important role in restricting 
cytokine responsiveness. To investigate the role of the basal 
promoter, we cloned the fragment - 189 to  - 7, containing 
the XGRR and the endogenous FeyRlb TATA-less  promoter 
into a luciferase reporter plasmid (Fig. 6 A). Transient trans- 
fection of this construct into U937 cells did not result in 
any significant  IFN-cz inducible  reporter gene expression 
whereas a 25-fold induction was observed after IFN-3, treat- 
ment (Fig. 8). By contrast, transfection of  XGRR-tk-luc (con- 
taining the XGRR upstream of  the heterologous tk promoter- 
luciferase rep.:,rter plasmid; Fig. 6 A) resulted in significant 
IFN-q, and IFN-o~ inducible expression (Fig. 8). This sug- 
gested (a) that U937 cells were capable of  responding to both 
IFN--y and IPN-ol;  and (b) that the ability of the XGRR 
to mediate dual cytokine responsiveness was dependent on 
the nature of the downstream promoter. One alternative ex- 
planation  was that the endogenous TATA-less  promoter in 
the construct 189/7-1uc contained a repressor element that 
silenced the IFN-ol inducibility of the upstream XGRR. To 
test this hypothesis, we transfected U937 cells with the con- 
struct 189/7-tk-luc (Fig. 6 A) in which the HSV-tk promoter 
was placed downstream of the XGRR and the endogenous 
FcyRlb basal promoter.  It was reasoned that in the event 
of active repression, the lack of IFN-ot inducibility would 
not be relieved by providing a TATA-based  promoter down- 
stream. Alternatively, if the IFN-ot responsiveness was de- 
pendent on a TATA box, addition of the HSV-tk promoter 
downstream should result in significant IFN-o~ inducibility. 
The results (Fig. 8; lane 189/7-tk-luc)  show equivalent re- 
sponsiveness to IFN-~, and IFN-cc A potential confounding 
variable is that the HSV-tk promoter also contains a Y-box 
element. The Y box has been shown to complement the ac- 
tivity of the H  and X boxes in the interferon inducibility 
of MHC class II gene expression (19). Since the XGRR also 
contains H  and X box-like  sequences, it was possible that 
the observed IFN-ol responsiveness was due to the presence 
of the Y box and not the TATA  element of the HSV-tk pro- 
moter.  To  evaluate  this  possibility,  we  introduced  the 
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Figure 8.  (A) Structure of the various luciferase constructs tested in 
B. (B) Luciferase activity assay of transiently transfected U937 and HeLa 
cells with  the  Fc3,Rlb promoter/XGRR  region constructs, assayed 
with/without IFN-'y or IFN-ol stimulation. U937 transfections: (Lane 
1) wt promoter/enhancer (189/7), 189/7-1uc; (Lane 2) XGRIL  in the con- 
text of the HSV-tk promoter, XGRR-tk-luc; (Lane 3) wt promoter/en- 
hancer (189/7) in the context of the HSV-tk  promoter, 189/7-tk-luc; (Lane 
4) wt promoter/enhancer (189/7) with AdML TATA box introduced at 
-113 to -105, 189/114-TATA-104/7-1uc;  (Lane  5) wt promoter/enhancer 
(189/7) with point mutation of the PU-box (-96 to -91), 189/7 APu- 
luc; (Lane 6) wt promoter/enhancer with PU-box mutation with AdML 
TATA box introduced at  -114 to -105, 189/114-TATA-104/7  APu-luc. 
HeLa transfections; (Lane 7) wt promoter/enhancer (189/7), 189/7-1uc; 
(Lane 8) wt promoter/enhancer (189/7) in the context of the HSV-tk  pro- 
moter, 189/7-tk-luc; (Lane 9) wt promoter/enhancer (189/7) with AdML 
TATA box introduced at -113 to -105, 189/114-TATA-104/7-1uc;  (Lane 
10) wt promoter/enhancer with PU-bo~  mutation with AdML TATA  box 
introduced at  -114 to  -105,  189/114-TATA-104/7  APu-luc. 
Adenovirus major late TATA box (AdML TATA) into the en- 
dogenous Fc3,Rlb promoter at bp  -113 (Figs.  1 and 6 A). 
This map position is  -30 bp from the major transcription 
start  site duster at  -82  and  -83 bp. In addition,  the site 
at which the TATA box was introduced did not contain an 
important  regulatory motif since introduction  of a restric- 
tion site at that position did not alter either basal or IFN- 
3,-indudble luciferase expression (results not shown). Tran- 
sient transfection of 189/114-TATA-104/7hic into U937 cells 
resulted in comparable induction of luciferase activity after 
both IFN-3'  and IFN-cz treatment. 
The implication that the endogenous TATA-less basal pro- 
moter was apparently restrictive for the type of the cytokine 
inducibility mediated by the XGRR prompted us to examine 
whether the insertion  of a TATA box may also permit ex- 
pression of Fc3,Rlb promoter in nonmyeloid cells.  In prior 
studies, we had observed that placing the XGRR in the con- 
text of the endogenous promoter restricted its activity in tran- 
sient transfection  systems to myeloid cells  (2).  We wished 
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to see whether the cons~cts 189/7 tk-luc and 189/114-TATA- 
104/7-Luc (Hg. 6 a) could restore the ability of the XGRR 
to function in nonmyeloid (Hda) cells.  Transient  transfec- 
tion of these constructs into HeLa ceils followed by IFN-3t 
or IFN-ot stimulation resulted in significant inducible responses 
to both cytokines (Fig. 8). This indicated that the TATA-less 
structure of the endogenous F~Klb basal promoter was not 
only restrictive for the type of cytokine inducibility medi- 
ated by the XGRR, it also appeared to play a role in res- 
tricting mydoid specificity of reporter gene expression as as- 
sayed by transient  transfection.  It is pertinent  to note that 
we have not performed primer extension assays to determine 
the precise transcription start sites of the reporter gene mRNA 
in these experiments due to the diffmulties  of obtaining good 
quality RNA from the subpopulation of transiently trans- 
fected cells that  actually received the transfected plasmid. 
Interestingly, the effects of the mutation in the PU.1 box 
that abrogate expression in the context of the physiologically 
relevant promoter could be reversed by introducing an AdML 
TATA-box upstream of the PIE region as in construct 189/ 
114-TATA-104/7-APu-Luc (Figs. 7 and 8). The presence of 
the TATA box in the above construct also had the effect of 
restoring IFN-c~ inducibility in addition to enabling reporter 
gene expression in HeLa cells  as well as U937 cells. 
Discussion 
We present data that demonstrates the presence of a func- 
tional PU.1 binding  site located within  a 21-bp conserved 
promoter element (PIE) of the mydoid restricted Fc"/R1 gene. 
We have also identified a loose Inr spanning two transcrip- 
tion start sites that serves a critical function in mediating tran- 
scription of this TATA-Iess gene. Mutation of either the PU.1 
motif or the Inr dement  abrogates basal transcription  and 
both of these sites  are essential for the IFN-3, inducibility 
of the gene.  Insertion of a strong TATA box permits inter- 
feron o~ responsiveness in addition to enhanced IFN-3,-medi- 
ated transcription.  The TATA containing plasmids are active 
in nonmyeloid cells  even in the context of an intact  PU.1 
site and Inr consensus.  We hypothesize that  the core pro- 
moter of the Fc~R1 may play an active role in regulating 
the gene's expression. 
A PU.1 binding site (GAGGAA) was identified on the lower 
strand of the PIE region and was shown to be functionally 
active.  A  10-bp linker mutation scan across the footprinted 
region (-104/-44)  confirmed that  the PU box was func- 
tionally active. A 3-bp mutation scan across the PIE region 
more precisely identified the core nucleotides of the PU motif. 
There was a direct correlation between in vitro binding ac- 
tivity of the mutant  constructs as determined by gel shift 
assays and in vivo expression in transient transfections of the 
same reporter gene constructs. Furthermore,  evidence for a 
human PU.l-like protein that bound to the PU box was de- 
rived from  competition  experiments  (results  not  shown). 
Excess unlabded oligonudeotides  containing  the PU con- 
sensus motif GAGGAA inhibited binding of the PIE region 
probe to the B1 complex. The B1 complex comigrated with 
in vitro translated PU.1 protein in a gel shift assay and both of these complexes could be supershifted to a similar posi- 
tion on the gd by anti-PU.1 antiserum. 
PU.1 has been shown to function in association with other 
factors (31, 33, 34, 36, 46). In the mouse immunoglobulin 
K 3' enhancer for example, PU.1 recruits a second B cell re- 
stricted factor, NF-EM5 (31). It is therefore possible that the 
PIE region provides a composite  binding platform for a PU.1- 
like factor and associated proteins. Some support for this idea 
arises from the 3-bp linker scan of the PIE region (Fig. 5, 
A and B). Mutations within the core GAGGAA resulted in 
loss of binding of complexes B1 and B2 (Fig.  5, A, lanes 
4, 5, and 6), whereas mutations of the peripheral nucleotides 
resulted in an altered pattern and intensity of binding of the 
complexes (Fig. 5 A, lanes 3 and 7). It is possible that if there 
is a distinct associated factor, its binding may be dependent 
on the prior binding of PU.1 as has been shown to be the 
case in the immunoglobulin X2-4 enhancer (33). 
The B2  complex most likely  represents  a  degradation 
product of B1. The middle of the PU.1 protein contains a 
so-called PEST region composed of the amino acids proline 
(P), glutamic acid (E), serine (S), and threonine (T) which 
is susceptible to protease degradation (28, 31). The anti-PU.1 
serum directed against  the NH2  terminus of the protein 
resulted in a supershift of only complex B1 in band shift assays. 
The failure of the antiserum to recognize the lower B2 com- 
plex may be consistent with its being a degradation product 
(47). An association between B1 and B2 could be tested using 
a polyclonal antiserum raised against the whole PU.1 pro- 
tein. Failure to supershift complex B2 would indicate that 
it is a distinct complex. Carvalho and Derse (47) showed that 
different anti-PU.1 sera resulted in different patterns of su- 
pershifted complexes. Our results indicate the presence of three 
complexes in the mydoid cell lines tested (U937, PLB, HL60, 
THP1). Perez et al. (48) describe a similar set of complexes 
(MATE-BP1, MATE-BP2, MATE-BP3) that bind this region 
of the Fc~Rlb promoter in extracts isolated from THP1 cells. 
However,  these authors do not detect the slower migrating 
complexes in extracts  from U937 and HL60 cells. One ex- 
planation for  this  difference  is  proteolysis  of the  slower 
migrating complexes. 
Since PU.1 is expressed in both B cells and macrophages, 
it seems that it cannot alone account for the mydoid specificity 
of the Fcq,  Rlb gene. Other factors must be involved to achieve 
such lineage specificity. These putative factors may lie out- 
side the PIE region. We show the sequence GCAAT overlap- 
ping the 5' end of the PIE is functionally active (Fig. 6 B, 
construct ACAAT), and it is possible that a factor binding 
this sequence may act in combination with PU.1 to achieve 
lineage restriction. A  similar motif, G/CCAAT, is known 
to bind members of the C/EBP family of proteins in myeloid 
cells (21, 49). 
The insertion of a strong (AdML) TATA box at a position 
30 bp upstream of the major transcription start site or in 
the form of atk promoter (in pGLO2) abrogates the tissue 
restricted expression of the promoter and allows it to func- 
tion in nonmyeloid cells. Furthermore, we show that inser- 
tion of such a TATA box renders  the promoter responsive 
not only to IFN-% but also to IFN-o~. Both lineage-restricted 
expression of the gene and its selective  responsiveness to IFN-'y 
are thus abrogated by insertion of a TATA box into the en- 
dogenous TATA-hss promoter. The PU motif is essential for 
both the IFN responsiveness of the gene and core promoter 
activity. 
Recently, it has been reported that the tumor suppressor 
protein p53 specifically represses transcription from TATA- 
containing promoters, but has no effect on initiator-mediated 
transcription (50). It is conceivable that in the Fcq,  R1 TATA- 
less promoter, the PU.1 factor exerts a repressive effect on 
the initiator element through interaction with the basal tran- 
scription factors. Our results may therefore be explained by 
the proposition that a cell-mediated activator, like PU.1, when 
placed in the context of a relatively weak transcription initi- 
ator may act as a bridging factor between the upstream IFN-y 
enhancer and the preinitiation complex. PU.1 is able to in- 
teract in vitro with the general transcription factor TFIID 
as has recently shown been shown (36). As Inr directed tran- 
scription in the absence of a TATA box requires TFIID con- 
sisting of TATA binding protein and its associated factors 
(transcription-associated factors) (40, 41, 51, 52), link between 
these key elements can be envisioned. In the absence of a TATA 
box, the ability of the Inr to direct assembly of the preinitia- 
tion complex depends on its strength (37). Strong initiators, 
like that of the Tdt promoter, are capable of initiation in the 
absence of a functional TATA box (37,  53, 54).  However, 
weak initiators have been shown to require, and indeed func- 
tion in cooperation with, a functional TAT dement (reviewed 
in reference 53 and references therein). The Fc'yRlb gene pro- 
moter has a weak Inr consensus and no functional TATA  box. 
In this case, the ability of PU.1 and PU.l-associated factor(s) 
to interact with and stabilize TFIID on the basal promoter 
may be critical in allowing assembly of the preinitiation com- 
plex upon the weak Int. Such a scheme may also account 
for the myeloid specific restriction of Fc'yKlb gene expres- 
sion. Assembly of basal transcription factors on the TATA- 
less promoter would be dependent on the existence of both 
PU.1 as well as PU.1  associated proteins. The observation 
that the Fc3,K1 gene is not expressed in B cells may be due 
to the unavailability  of these additional PU.1 associated in 
B lymphocytes. The mechanisms by which a TATA  box relieves 
the PU.1/Inr restriction of interferon responsiveness is not 
known, but these findings bring into focus the potentially 
important role of the structure of the basal promoter in de- 
termining the restriction of gene expression. 
We are grateful to Dr. Richard Maki for providing invaluable reagents and to Drs. Stuart Orkin, Jeff 
Ravetch, Dan Tenen, Renate Schiebe,  and members of our laboratory for helpful discussions.  We especially 
appreciate Dr. Steven Smale's invaluable advice and critical review of the manuscript. 
1994  PU.1 Factor and Initiator Element Fc~yRlb Gene Expression This work is supported by National Institutes of Health grant KO1 AI-23786 and MO1 KR-02171. Q. 
Eichbaum is a Cancer l~search Institute Postdoctoral Fellow and R. A. B. Ezekowitz in an Established 
Investigator of the American Heart Association. 
Address correspondence to Dr.  K. Alan B.  Ezekowitz,  Division of Infectious Diseases and Hema- 
tology/Oncology, Children's  Hospital, Harvard Medical  School, 300 Longwood Avenue,  Boston, MA 02115. 
Received for publication 17 November  1993 and in revised  form  I4 February I994. 
References 
1.  Pearse, R.N., R. Feinman, andJ.V. Ravetch. 1991. Character- 
ization of the human Fc-3, R1 gene promoter: transcriptional 
induction by 3' interferon is mediated through common DNA 
response elements. Proa Natl. Acad. Sci. USA.  88:11305. 
2.  Benech,  P.D., K. Sastry, K.R. lyer, Q.G. Eichbaum,  D.P. Raveh, 
and R.A.B. Ezekowitz. 1992. Definition of interferon 3'-re- 
sponse elements in a novel human Fc3" receptor (Fc3dLlb)  and 
characterization of the gene structure.J. ExI~ Med. 176:1115. 
3.  Wilson, K.C., and D.S. Finbloom. 1992. Interferon 3' rapidly 
induces in human monocytes  a DNA-binding factor that recog- 
nizes the gamma response region within the promoter of the 
gene for the high-affinity Fc'lr receptor. Proc Natl. Acad. Sci. 
USA.  89:11964. 
4.  Auget, M., Z. Dembic, and G. Merlan. 1988. Molecular  cloning 
and expression of the human interferon  3' receptor. Ceil 55:273. 
5.  Schindler, C., K. Shuai, V.K. Prezioso, and J.E. Darnell, Jr. 
1992. Interferon-3, dependent tyrosine phosphorylation of a 
latent  cytoplasmic transcription factor. Science (Wash. DC). 
257:809. 
6.  Shuai, K., C. Schindler, V.R. Prezioso, andJ.E. Damell. 1992. 
Activation of transcription by IFN-3': tyrosine phosphoryla- 
tion of a 91-kD DNA binding protein. Science (wash. DC). 
258:1808. 
7.  Shuai, K., G.K. Stark, I.M. Kerr, and J.E. Daruell, Jr. 1993. 
A single phosphotyrosine residue of Star91 required for gene 
activation by interferon-3". Science (Wash. DC). 261:1744. 
8.  Fu, X., C. Schindler,  T. Improta, K. Aebersold, andJ.E. Dar- 
nell. 1992. The proteins of ISGF-3, the interferon ol-induced 
transcriptional  activator, define  a gene family  involved  in signal 
transduction. Pro~ Natl. Acad. Sci. USA.  89:7840. 
9.  Kessler, D.S., S.A. Veals, X.-Y. PU, and D.E.  Levy. 1990. 
Inteferon-ol  regulates nuclear translocation and DNA-binding 
affinity of ISGF3, a multimeric transcriptional activator. Genes 
& Dev. 4:1753. 
10.  Levy,  D.E., D.S. Kessler, K. Pine, and J.E. Darnell, Jr. 1989. 
Cytoplasmic activation of ISGF3, the positive regulator of 
interferon-cz stimulated transcription, reconstituted In Vitra 
Genes & Dev. 3:1362. 
11. Dale, T.C., A.M.A. Imam, I.M. Kerr, and G.K. Stark. 1989. 
Rapid activation by interferon tx of  a latent DNA-binding pro- 
tein present in the cytoplasm  of  untreated cells. Pr0~ Natl. Acad. 
Sci. USA.  86:1203. 
12. Lamer, A.C., M. David, G.M. Feldman, K. Igarashi, R.H. 
Hackett, D.S.A. Webb, S.M. Sweitzer, E.F. Petricoin III, and 
D.S. Finbloom.  1993. Tyrosine phosphorylation  of DNA 
binding proteins by multiple cytokines. Science (Wash. DC). 
261:1730. 
13.  Silvennoinen,  O., C. Schindler,  J. Schlessinger,  and D.E. Levy. 
1993. Ras-independent growth factor signaling by transcrip- 
tion  factor  tyrosine phosphorylation.  Science (Wash. DC). 
261:1736. 
1995  Eichbaum  et al. 
14.  Ruff-Jamison, S., K. Chen,  and S. Cohen.  1993. Induction 
by EGF and interferon-3' to tyrosine phosphorylated DNA 
binding proteins in mouse liver nuclei. Science (Wash. DC). 
261:1733. 
15.  Sadowski,  H.B., K. Shuai,  J.E. Darnell, Jr., and M.Z. Gilman. 
1993. A common nuclear signal transduction pathway acti- 
vated by growth factor and cytokine receptors. Science (Wash. 
DC). 261:1739. 
16.  Montminy, M. 1993. Trying on a new pair of SH2s. Science 
(Wash. DC). 261:1694. 
17. Decker, T., D.J. Lew,  J. Mizkovitch,  andJ.E. Daruell, Jr. 1991. 
Cytoplasmic  activation  of  GAF, an interferon-3,  regulated  DNA- 
binding factor. EMBO (Fur. Mol. Biol. Organ.)J. 10:927. 
18.  pearse, R..N., K. Feinman, K. Shuai, J.E. Daruell, Jr., andJ.V. 
Ravetch. 1993. Interferon 3"-induced  transcription of the high- 
affinity Fc receptor for IgG requires assembly of a complex 
that includes  the 91-kDa subunit of transcription factor ISGF3. 
Pror Natl. Acad. Sci. USA. 90:4314. 
19. Benoist, C., and D. Mathis. 1990. Regulation of major histo- 
compatibility complex class II genes: X, Y, and other letters 
of the alphabet. Annu. Rev. Immunol. 9:457. 
20.  LaMarco, K.L., and S.L. McKnight.  1989. Purification of a 
set of  cellular  polypeptides  that bind to purine rich cis-regulatory 
elements of  herpes simplex  virus immediate early genes. Genes 
& Dev. 3:1372. 
21.  Suzow,  J., and A.D. Friedman. 1993. The murine myeloperox- 
idase promoter contains several functional elements, one of 
which binds a cell type-restricted transcription factor, myeloid 
nuclear factor 1 (MyNF1). Mol. Cell. Biol. 13:2141. 
22.  Takahashi,  H., T. Nukiwa, K. Yoshimura, C.D. Quick, D.J. 
States, M.D. Holmes, J. Whang-Peng, T. Knutsen, and K.G. 
Crystal. 1988. Structure of the human neutrophil elastase  gene. 
J. Biol. Chem. 263:14739. 
23.  Skalnick, D.G., E.C. Strauss, and S.H. Orkin. 1991. CCAAT- 
displacement protein as a repressor of the mydomonocytic- 
spedfic gp91-phox gene promoter. J. Biol. Chem. 266:16736. 
24.  Alcalay, M., F. Antolini, W.J. Van de Ven, L. Lanfrancone, 
F. Grignani, and P.G. Pelicci. 1990. Characterization of  human 
and mouse c-los cDNA clones and identification of the 5' end 
of the gene. Oncogene. 5:267. 
25.  Galas,  D., and A. Schmitz. 1978. DNase foot-printing: a simple 
method for the detection of protein-DNA binding specificity. 
Nucleic Acids Res. 5:3157. 
26.  Wright, T.M., and J.M. Farber. 1991. 5' regulatory region of 
a novel cytokine gene mediates selective activation by inter- 
feron % j. EXl~ Med. 173:417. 
27.  Hohn, P.A., N.C. popuescu, lL.D. Hanson, G. Salvesen, and 
T.J. Ley.  1989. Genomic organization and chromosomal local- 
ization of the human cathepsin  G gene.J. Biol. Chem. 264:13412. 
28.  Klemsz, M.J., S.K. McKercher, A. Celada, C. van Beveren, 
and K.A. Maid. 1990. The macrophage  and B cell-specific  tran- scription factor Pu.1 is related to its oncogene. Cell. 61:113. 
29.  Macleod, K., D. Leprince, and D. Stehelin. 1992. The ets gene 
family. TIBS (Trends Biochem. Sci.). 199:251. 
30.  Karim, F.D., L.D. Umess, C.S. Thummel, M.J. Klemsz, S.R. 
McKercher, A. Celada, C. van Beveren, R.A. Maki, C.V. Gun- 
ther, J.A. Nye, and 13.I. Graves. 1990. The ETS-domain: a new 
DNA-binding motif that recognizes a purine-rich core DNA 
sequence. Genes & Dev. 4:1451. 
31.  Pongubala, J.M.R., S. Nagulapalli, M.J. Klemsz, S.R. Mc- 
Kercher, R.A. Maki, and M.L. Atchison. 1992. PU.1 recruits 
a second nuclear factor to a site important for immunoglob- 
ulin K3' enhancer activity. Mol. Cell. Biol. 12:368. 
32.  Pongubala, J.M.R.C.  van  Beveren, S.  Nagulapalli,  M.J. 
Klemsz, S.R.  McKercher, R.A. Maki, and M.L.  Atchison. 
1993. Effect of  PU.1 phosphoryhtion on interaction with NF- 
EM5 and transcriptional activation. Science (Wash. DC). 259: 
1622. 
33.  Eisenbeis, C.F., H. Singh, and U. Storb. 1993. PU.1 is a com- 
ponent of a multiprotein complex which binds an essential site 
in the murine immunoglobulin # 2-4 enhancer. Mol. Cell. Biol. 
13:6452. 
34.  Chen, H.M., H.L. Pahl, R.J. Scheibe, D.E. Zhang, and D.G. 
Tenen. 1993. The SpI transcription  factor binds the CDllb 
promoter specifically  in myeloid cells in v/vo and is essential 
for myeloid-specific  promoter activity.J. Biol. Chem. 268:8230. 
35.  Grove,  M., and M. Plumb. 1993. C/EBP, NF-kB, and c-Ets 
family  members and transcriptional  regulation of  the cell-specific 
and inducible  macrophage  inflammatory  protein 1 o~ immediate- 
early gene. Mol. Cell. Biol. 13:5278. 
36.  Hagemeier, C., A.J. Bannister, A. Cook, and T. Kouzarides. 
1993. The activation domain of transcription factor PU.1 binds 
the retinoblastoma (R.B) protein and the transcription factor 
TFIID in vitro: RB shows sequence similarity to TFIID and 
TFIIB. Pro~ Natl. Acad. Sci. USA.  90:1580. 
37.  Smale, S.T. 1994. Core promoter architecture for eukaryotic 
protein-coding genes. In Transcription: Mechanisms and Regu- 
lation. J. Conaway and R. Conaway, editors. Raven Press, New 
York. 63-81. 
38.  Zenzie-Gregory, B.,  A.  O'Shea-Greenfield, and  S.T. Smale. 
1992. Similar mechanisms for transcription  initiation  medi- 
ated through a TATA  box or an initiator element.J. Biol. Chem. 
267:2823. 
39.  Zenzie-Gregory, B., A. Khachi, I.P. Garraway, and S.T. Smale. 
1993. Mechanism of initiator-mediated transcription: evidence 
for a functional interaction between the TATA-binding pro- 
tein and DNA in the absence  of  a specific  recognition sequence. 
Mol. Cell. Biol. 13:3841. 
40.  Roy, A.L., M. Meisterernst, P. Pognonec, and R.C. Roeder. 
1991. Cooperative interaction of  an imtiator-binding transcrip- 
tion initiation factor and the helix-loop helix-activator USE 
Nature (Lond.). 354:245. 
41.  Shi, Y., E. Seto, L.-S. Cheng, and T. Shenk. 1991. Transcrip- 
tional repression by YY1 a human GLI-Kruppel-related pro- 
tein and relief of repression by Adenovirns Ela protein. Cell. 
67:377. 
42.  Diguam, J.E., P.I. Martin, B.S. Shastry, and R.G. Roeder. 1983. 
Eukaryotic gene transcription with purified components. Me- 
thods Enzymol.  101:582. 
43.  Lichtsteiner,  S., J. Wuarin, and U. Schibler. 1987. DNA-binding 
proteins on the promoter of the mouse albumin gene. Cell. 
51:963. 
44.  Iyer,  R.R. 1991. A matched set of CAT vectors for rapid mu- 
tation analysis of eukaryotic promoters and enhancers. Gene. 
105:97. 
45.  Zaret, K.S., J.-K. Liu, and C.M. Dil~rsio. 1990. Site-directed 
mutagenesis reveals  a liver transcription factor essential for the 
albumin transcriptional enhancer. Pro~ Natl. Acad. Sci. USA. 
87:5469. 
46.  Galson, D.L., J.O. Hensold, T.R. Bishop, M. Schalling, A.D. 
D'Andrea, C. Jones, P.E. Auron, and D.E. Housman.  1993. 
Mouse B-globin  DNA-binding protein B1 is identical to a proto- 
oncogene, the transcription factor Spi-1/PU.1, and is restricted 
in expression to hematopoietic cells and the testis. Mol. Cell. 
Biol. 13:2929. 
47.  Carvalho, M., and D.  Derse.  1993. The PU.1/Spi-1 proto- 
oncogene is a transcriptional regulator of a lentivirus promoter. 
J.  Virol. 67:3885. 
48.  t~ez, C., J. Wietzerbin, and P.D. Benech. 1993. Two cis-DNA 
elements involved  in myeloid-cell-specific  expression and 3' in- 
terferon activation of the human  high-affinity Fc  3, receptor 
gene: a novel interferon regulatory mechanism. Mol. Cell. Biol. 
13:2182. 
49.  Scott, L.M., C.I. Civin, P. Rorth, and A.D. Friedman. 1992. 
A novel expression pattern of three C/EBP family members 
in differentiating myelomonocytic cells. B/ood. 80:1725. 
50.  Mack, D.H., J. Vartikar,  J.M. Pipas, and L.A. Laimins. 1993. 
Specific  repression  of  TATA-mediated  but not initiator-mediated 
transcription by wild-type p53. Nature (land.).  363:281, 
51.  Scto, E.,  Y.  Shi, and  T.  Shenk.  1991. YYI  is an  initiator 
sequence-binding protein that directs and activates transcrip- 
tion in vitro. Nature (Lond.). 354:241. 
52.  Cormack, B.P., and K. Struhl. 1992. The TATA-binding  pro- 
tein is required for transcription by all three nuclear RNA poly- 
merases in yeast cells. Cell. 69:685. 
53.  Hernandez,  N.  1993. TBP, a universal eukaryotic transcrip- 
tion factor? Genes & Dev. 7:1291. 
54.  Smale, S.T., and D. Baltimore. 1989. The 'initiator' as a tran- 
scription control element.  Cell. 57:103. 
1996  PU.1 Factor and Initiator Element Fc3,Rlb Gene Expression 